DDInter1340 DDInter916
Originally approved by the FDA in 1989, omeprazole is a _proton-pump inhibitor_, used to treat gastric acid-related disorders. These disorders may include gastroesophageal reflux disease (GERD), peptic ulcer disease, and other diseases characterized by the oversecretion of gastric acid. This drug was the first clinical useful drug in its class, and its approval was followed by the formulation of many other proton pump inhibitor drugs. Omeprazole is generally effective and well-tolerated, promoting its popular use in children and adults [FDA label].
The most significant modifiable risk factor for cardiovascular disease and the most prominent contributor to all-cause mortality is hypertension. Characterized by an office blood pressure of ≥140/90, hypertension is pervasive and impacts an estimated 25% of adults globally. Treatment for hypertension should include a number of lifestyle changes (ie. reduced sodium intake) along with pharmacotherapy - it should be noted that treatment with several antihypertensive agents may be required in order to achieve blood pressure targets. Thiazide-like diuretics such as indapamide are a valuable tool for the treatment of hypertension and continue to grow in popularity, falling behind only ACE inhibitors in terms of prescription frequency. When compared to [hydrochlorothiazide] (another commonly prescribed diuretic), indapamide has been shown to be superior at lowering systolic blood pressure, reducing left ventricular mass index, lowering oxidative stress, inhibiting platelet aggregation, and reducing microalbuminuria associated with diabetes. Interestingly, unlike thiazide diuretics, several sources suggest that indapamide is not associated with glucose or lipid disturbances.[A204134,A204161] Indapamide is characterized by both a methylindoline and a sulfamoyl chlorobenzamide functional group, with the former being largely responsible for the molecule’s lipid solubility.
Omeprazole {u} (Compound) binds {v} (Gene) CYP3A4
CYP3A4 {u} (Gene) is bound by {v} (Compound) Indapamide
Omeprazole {u} (Compound) causes {v} (Side Effect) Jaundice
Jaundice {u} (Side Effect) is caused by {v} (Compound) Indapamide
Omeprazole {u} (Compound) resembles {v} (Compound) Pantoprazole
Pantoprazole {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Indapamide
Omeprazole {u} (Compound) resembles {v} (Compound) Lansoprazole
Lansoprazole {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Indapamide
Omeprazole {u} (Compound) resembles {v} (Compound) Rabeprazole
Rabeprazole {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Indapamide
Omeprazole {u} (Compound) binds {v} (Gene) CYP3A4
CYP3A4 {u} (Gene) is bound by {v} (Compound) Oxcarbazepine
Oxcarbazepine {u} (Compound) resembles {v} (Compound) Indapamide
Omeprazole {u} (Compound) causes {v} (Side Effect) Jaundice
Jaundice {u} (Side Effect) is caused by {v} (Compound) Chlorthalidone
Chlorthalidone {u} (Compound) resembles {v} (Compound) Indapamide
Omeprazole {u} (Compound) causes {v} (Side Effect) Depression
Depression {u} (Side Effect) is caused by {v} (Compound) Atropine
Atropine {u} may cause a minor interaction that can limit clinical effects when taken with {v} Indapamide
Omeprazole {u} (Compound) causes {v} (Side Effect) Stomatitis
Stomatitis {u} (Side Effect) is caused by {v} (Compound) Oxcarbazepine
Oxcarbazepine {u} (Compound) resembles {v} (Compound) Indapamide
Omeprazole {u} (Compound) causes {v} (Side Effect) Gastroenteritis
Gastroenteritis {u} (Side Effect) is caused by {v} (Compound) Glycopyrronium
Glycopyrronium {u} may cause a minor interaction that can limit clinical effects when taken with {v} Indapamide
Omeprazole (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Indapamide (Compound)
Omeprazole (Compound) causes Jaundice (Side Effect) and Jaundice (Side Effect) is caused by Indapamide (Compound)
Omeprazole (Compound) resembles Pantoprazole (Compound) and Pantoprazole may cause a moderate interaction that could exacerbate diseases when taken with Indapamide
Omeprazole (Compound) resembles Lansoprazole (Compound) and Lansoprazole may cause a moderate interaction that could exacerbate diseases when taken with Indapamide
Omeprazole (Compound) resembles Rabeprazole (Compound) and Rabeprazole may cause a moderate interaction that could exacerbate diseases when taken with Indapamide
Omeprazole (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Oxcarbazepine (Compound) and Oxcarbazepine (Compound) resembles Indapamide (Compound)
Omeprazole (Compound) causes Jaundice (Side Effect) and Jaundice (Side Effect) is caused by Chlorthalidone (Compound) and Chlorthalidone (Compound) resembles Indapamide (Compound)
Omeprazole (Compound) causes Depression (Side Effect) and Depression (Side Effect) is caused by Atropine (Compound) and Atropine may cause a minor interaction that can limit clinical effects when taken with Indapamide
Omeprazole (Compound) causes Stomatitis (Side Effect) and Stomatitis (Side Effect) is caused by Oxcarbazepine (Compound) and Oxcarbazepine (Compound) resembles Indapamide (Compound)
Omeprazole (Compound) causes Gastroenteritis (Side Effect) and Gastroenteritis (Side Effect) is caused by Glycopyrronium (Compound) and Glycopyrronium may cause a minor interaction that can limit clinical effects when taken with Indapamide